how do glp 1 work GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes How glucagon-like peptide 1 receptor
Description
Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels
Triple agonist (GLP-1/GIP/Glucagon), under clinical investigation
| 228 comments on LinkedIn
The WHO released new guidance on GLP-1 medications for adults with obesity, recommending their long-term, continuous usewhen clinically appropriate.
Recently, the introduction of highly effective glucagon-like peptide-1 (GLP-1) receptor agonists has led to increased utilization of obesity medications in this population
